Sarcoma patients share their experience on a second chemo round
NCT ID NCT06050434
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to track how soft tissue sarcoma patients feel—symptoms, side effects, and quality of life—when they receive trabectedin chemotherapy again after a break. Only 7 patients were enrolled before the study was stopped early. The goal was to gather real-world patient feedback to guide future treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trabectedin (chemotherapy)
What this could lead to
If successful, this study could help doctors understand how sarcoma patients feel during a second round of trabectedin, potentially improving care decisions.
What could go wrong
This was a small, terminated study with only 7 participants, so results may be limited and not apply to all patients. It focuses on patient reports, not on proving the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Frankfurt Universitätsklinikum
Frankfurt am Main, Germany
-
HELIOS KLinikum Bad Saarow
Bad Saarow, Germany
-
HELIOS Klinikum Berlin Buch
Berlin, Germany
-
Uniklinikum Leipzig
Leipzig, Germany
-
Universitätsklinikum Tübingen
Tübingen, Germany
-
Universitätsmedizin Greifswald
Greifswald, Germany
-
Universitätsmedizin Göttingen
Göttingen, Germany
-
Universitätsmedizin Mainz
Mainz, Germany
-
Westfälische Wilhelms-Universität Münster
Münster, Germany